Prédicteurs moléculaires et nouvelles cibles en oncologie (PMNCO)

Laboratory presentation

This unit works on the identification and validation of new therapeutic targets as well as molecular predictors in oncology. This work is based on the principle of high-throughput molecular characterization in order to identify therapeutic targets. The mission of this team is to transfer molecular knowledge to clinical practice, and to use patient samples as a source of research hypotheses. One of the objectives is the setting up of clinical trials to test biomarkers, the second is project management or in support of other units performing fondamental research for translational research. Technology development and bioinformatics tools for translational research is one of the objectives of this unit.

The 20 latest publications

Title Authors Publication date Source
Diffuse midline glioma invasion and metastasis rely on cell-autonomous signaling Marco Bruschi, Yassine Ajlil, Stephanie Vairy, Manon Lancien, Samia Ghermaoui, Thomas Kergrohen, Kévin Beccaria, Jacques Grill, Marie Anne Debily, David Castel 03/01/24 Neuro-Oncology
Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial Sophie Postel-Vinay, Anas Gazzah 02/24/24 British Journal of Cancer
Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201 Y. Loriot 02/01/24 Annals of Oncology
Correction: Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers (Cell Death & Disease, (2021), 12, 3, (258), 10.1038/s41419-021-03540-y) François Xavier Danlos, Jean Eudes Fahrner, Anne Goubet, Agathe Dubuisson, Lisa Derosa, Delphine Bredel, Séverine Mouraud, Laurence Zitvogel, Aurélien Marabelle 02/01/24 Cell Death and Disease
Plain language summary of erdafitinib in locally advanced or metastatic urothelial carcinoma: a phase 2 study with long-term follow-up Y. Loriot 02/01/24 Future Oncology
Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients Fabrice André 01/10/24 Clinical Cancer Research
Pregnancy after Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study Antonio Di Meglio, Camila Chiodi 01/02/24 JAMA - Journal of the American Medical Association
An effort to improve the collection of patient-generated data: readability and understandability of patient-reported outcomes measures in a survivorship cohort Camila Chiodi, Johanna Arvis, E. Martin, Aude Barbier, Antonio Di Meglio, Emma Gillanders, G. Menvielle, Ines Vaz Luis, Maria Alice Franzoi 01/01/24 Quality of Life Research
Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer Y. Loriot 01/01/24 Annals of Oncology
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial Y. Loriot 01/01/24 Annals of Oncology
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions Y. Loriot 01/01/24 Nature Reviews Clinical Oncology
Response to Sorscher Barbara Pistilli 01/01/24 Journal of the National Cancer Institute
Arterial hypertension associated with PARPi: A meta-analysis of 41 placebo randomized controlled trials combined with a World Health Organization's pharmacovigilance study Sophie Postel-Vinay 01/01/24 Fundamental and Clinical Pharmacology
Changing cancer representations toward comprehensive portraits to empower patients in their care journey Maria Alice Franzoi, Ines Vaz-Luis 12/01/23 Annals of Oncology
WGS/WES-RNAseq compared to targeted NGS in oncology: is there something to unlock? Sergey I. Nikolaev 12/01/23 Annals of Oncology
Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer Damien Vasseur 12/01/23 European Journal of Cancer
Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study Federica Giugliano 12/01/23 European Journal of Cancer
Genomic mutation landscape of skin cancers from DNA repair-deficient xeroderma pigmentosum patients P. L. Kannouche, Alain Sarasin 12/01/23 Nature Communications
Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome Olivier Ayrault, Jacob Torrejon 12/01/23 Neuro-Oncology
Homologous recombination deficiency (HRD) testing on cell-free tumor DNA from peritoneal fluid Felix Blanc-Durand, Audrey Le Formal, Laure Chardin, Elisa Yaniz, Etienne Rouleau, Alexandra Leary 12/01/23 Molecular Cancer

Number of publications of the laboratory by scientific field (2016-2021)

Every paper can be classified in one or more scientific fields. The figure below shows the lab's number of publications in each scientific field, according to the ASJC classification (Elsevier)